Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. more
Time Frame | PYPD | Sector | S&P500 |
---|---|---|---|
1-Week Return | 23.37% | -2.12% | -3% |
1-Month Return | -7.74% | -3.42% | -0.73% |
3-Month Return | -6.94% | -11.13% | 2.87% |
6-Month Return | -19.5% | -5.74% | 7.17% |
1-Year Return | -17.99% | 3.97% | 25.31% |
3-Year Return | -98.12% | 1.05% | 28.38% |
5-Year Return | -99.44% | 34.37% | 81.89% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 947.00K | 1.01M | 1.12M | 1.72M | 1.82M | [{"date":"2019-12-31","value":51.98,"profit":true},{"date":"2020-12-31","value":55.54,"profit":true},{"date":"2021-12-31","value":61.36,"profit":true},{"date":"2022-12-31","value":94.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (947.00K) | (1.01M) | (1.12M) | (1.72M) | (1.82M) | [{"date":"2019-12-31","value":-94700000,"profit":false},{"date":"2020-12-31","value":-101200000,"profit":false},{"date":"2021-12-31","value":-111800000,"profit":false},{"date":"2022-12-31","value":-172100000,"profit":false},{"date":"2023-12-31","value":-182200000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 18.56M | 26.27M | 42.88M | 38.89M | 21.05M | [{"date":"2019-12-31","value":43.29,"profit":true},{"date":"2020-12-31","value":61.28,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.7,"profit":true},{"date":"2023-12-31","value":49.08,"profit":true}] |
Operating Income | (18.56M) | (26.27M) | (42.88M) | (38.89M) | (22.87M) | [{"date":"2019-12-31","value":-1856000000,"profit":false},{"date":"2020-12-31","value":-2627200000,"profit":false},{"date":"2021-12-31","value":-4287500000,"profit":false},{"date":"2022-12-31","value":-3888800000,"profit":false},{"date":"2023-12-31","value":-2286700000,"profit":false}] |
Total Non-Operating Income/Expense | 11.70M | (21.19M) | 1.09M | (1.08M) | (1.94M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-181.15,"profit":false},{"date":"2021-12-31","value":9.3,"profit":true},{"date":"2022-12-31","value":-9.23,"profit":false},{"date":"2023-12-31","value":-16.6,"profit":false}] |
Pre-Tax Income | (6.91M) | (36.87M) | (42.33M) | (39.43M) | (23.80M) | [{"date":"2019-12-31","value":-690500000,"profit":false},{"date":"2020-12-31","value":-3686900000,"profit":false},{"date":"2021-12-31","value":-4233100000,"profit":false},{"date":"2022-12-31","value":-3942800000,"profit":false},{"date":"2023-12-31","value":-2379600000,"profit":false}] |
Income Taxes | (11.65M) | (1.54M) | (1.62M) | 97.00K | 69.00K | [{"date":"2019-12-31","value":-12015.46,"profit":false},{"date":"2020-12-31","value":-1592.78,"profit":false},{"date":"2021-12-31","value":-1668.04,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":71.13,"profit":true}] |
Income After Taxes | 4.75M | (35.32M) | (40.71M) | (39.52M) | (23.86M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-743.66,"profit":false},{"date":"2021-12-31","value":-857.12,"profit":false},{"date":"2022-12-31","value":-832.11,"profit":false},{"date":"2023-12-31","value":-502.42,"profit":false}] |
Income From Continuous Operations | (6.91M) | (36.87M) | (42.33M) | (39.52M) | (24.08M) | [{"date":"2019-12-31","value":-690500000,"profit":false},{"date":"2020-12-31","value":-3686900000,"profit":false},{"date":"2021-12-31","value":-4233100000,"profit":false},{"date":"2022-12-31","value":-3952500000,"profit":false},{"date":"2023-12-31","value":-2407600000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 4.75M | (35.32M) | (40.71M) | (39.52M) | (23.86M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-743.66,"profit":false},{"date":"2021-12-31","value":-857.12,"profit":false},{"date":"2022-12-31","value":-832.11,"profit":false},{"date":"2023-12-31","value":-502.42,"profit":false}] |
EPS (Diluted) | - | (7.46) | (2.27) | (2.04) | (7.78) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-745.5,"profit":false},{"date":"2021-12-31","value":-227,"profit":false},{"date":"2022-12-31","value":-204,"profit":false},{"date":"2023-12-31","value":-778,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
PYPD | |
---|---|
Cash Ratio | 0.91 |
Current Ratio | 1.00 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
PYPD | |
---|---|
ROA (LTM) | -64.65% |
ROE (LTM) | -496.62% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
PYPD | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.89 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.11 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
PYPD | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 9.05 |
EV/R | 0.00 |
EV/Ebitda | NM |
PolyPid (PYPD) share price today is $3.22
Yes, Indians can buy shares of PolyPid (PYPD) on Vested. To buy PolyPid from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PYPD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of PolyPid (PYPD) via the Vested app. You can start investing in PolyPid (PYPD) with a minimum investment of $1.
You can invest in shares of PolyPid (PYPD) via Vested in three simple steps:
The 52-week high price of PolyPid (PYPD) is $9.2. The 52-week low price of PolyPid (PYPD) is $2.37.
The price-to-earnings (P/E) ratio of PolyPid (PYPD) is
The price-to-book (P/B) ratio of PolyPid (PYPD) is 9.05
The dividend yield of PolyPid (PYPD) is 0.00%
The market capitalization of PolyPid (PYPD) is $23.81M
The stock symbol (or ticker) of PolyPid is PYPD